# Apyx Medical Corp (APYX)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/apyx-medical-corp/ JSON: https://steadybase.io/company/apyx-medical-corp.json Checked Nov 10, 2026. Latest filing read: Nov 5, 2026.

## Company

- Legal name: Apyx Medical Corp
- Ticker: APYX (Nasdaq)
- SEC CIK: 0000719135
- Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
- Headquarters: Clearwater, FL
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: apyxmedical.com
- LinkedIn: https://www.linkedin.com/company/apyxmedical
- Next earnings date: Dec 18, 2026 (estimated from past 8-K timing)

## Key facts

- Revenue: $52.8M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/719135/000143774926007471/0001437749-26-007471-index.html
- Operating income: -$6.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/719135/000143774926007471/0001437749-26-007471-index.html
- Net income: -$11.2M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/719135/000143774926007471/0001437749-26-007471-index.html
- SG&A: $15.8M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 10, 2026). Source: https://www.sec.gov/Archives/edgar/data/719135/000143774926007471/0001437749-26-007471-index.html
- Employees: 205 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/719135/000143774926007471/apyx20251231_10k.htm
- Shares outstanding: 42,124,023 as of Nov 4, 2026 (10-Q filed Nov 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/719135/000143774926035127/0001437749-26-035127-index.html
- Auditor: Rsm Us LLP, Tampa, Florida, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/719135/000143774926007471/apyx20251231_10k.htm

## Business

Apyx Medical Corporation (“Company”, “Apyx Medical”, “we”, “us”, or “our”) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/719135/000143774926007471/apyx20251231_10k.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $52.8M | -$6.4M | -$11.2M | $15.8M |
| Dec 31, 2024 | $48.1M | -$18.8M | -$23.5M | $18.9M |
| Dec 31, 2023 | $52.3M | -$17.3M | -$18.7M | $22.2M |
| Dec 31, 2022 | $44.5M | -$23.6M | -$23.2M | $20.5M |
| Dec 31, 2021 | $48.5M | -$14.4M | -$15.2M | $18.6M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/apyx-medical-corp.json

## Officers and directors

- Charles D. Goodwin II, Chief Executive Officer. LinkedIn: https://linkedin.com/in/charlie-goodwin-1b294b3b. Source: Form 4 filed Jun 15, 2026, https://www.sec.gov/Archives/edgar/data/719135/000149315226028770/0001493152-26-028770-index.htm
- Matthew C. Hill, Chief Financial Officer. Source: Form 4 filed Jun 15, 2026, https://www.sec.gov/Archives/edgar/data/719135/000149315226028766/0001493152-26-028766-index.htm
- Shawn David Roman, Chief Operating Officer. Source: Form 4 filed Jun 17, 2026, https://www.sec.gov/Archives/edgar/data/719135/000149315226029122/0001493152-26-029122-index.htm
- Stavros Vizirgianakis, Chairperson of the Board. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/719135/000143774926007471/apyx20251231_10k.htm
- Moshe Citronowicz, Sr. V.P. of Operations. Source: Form 4 filed Jun 15, 2026, https://www.sec.gov/Archives/edgar/data/719135/000149315226028765/0001493152-26-028765-index.htm
- Lawrence J. Waldman, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/719135/000143774926007471/apyx20251231_10k.htm
- Minnie Baylor-Henry, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/719135/000143774926007471/apyx20251231_10k.htm
- Wendy Levine, Director. Source: 10-K filed Mar 10, 2026, https://www.sec.gov/Archives/edgar/data/719135/000143774926007471/apyx20251231_10k.htm
- Matthew Hill, Named in proxy. Source: DEF 14A filed Jun 26, 2026, https://www.sec.gov/Archives/edgar/data/719135/000143774926021840/apyx20260603_def14a.htm
- Shawn Roman, Named in proxy. Source: DEF 14A filed Jun 26, 2026, https://www.sec.gov/Archives/edgar/data/719135/000143774926021840/apyx20260603_def14a.htm

## Recent 8-K events

- Nov 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/719135/000143774926035079/apyx20260827_8k.htm
- Sep 29, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/719135/000143774926031468/apyx20260929_8k.htm
- Aug 7, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/719135/000149315226036557/form8-k.htm
- Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/719135/000143774926026262/apyx20260602_8k.htm
- Jul 24, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/719135/000149315226034619/form8-k.htm
- Jun 17, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/719135/000149315226029081/form8-k.htm
- May 21, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/719135/000143774926018098/apyx20260521_8k.htm
- May 14, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/719135/000143774926016885/apyx20260513_8k.htm
- May 11, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/719135/000143774926016000/apyx20260508_8k.htm
- May 7, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/719135/000143774926015352/apyx20260107_8k.htm

## What management said

- "We are pleased to report 17% growth in our Surgical Aesthetics business for the quarter, reflecting continued adoption of AYON and the progress we are making in executing our commercial strategy" Charlie Goodwin, President and Chief Executive Officer (8-K filed Nov 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/719135/000143774926035079/ex_1009950.htm

## Latest filings

- 8-K filed Sep 29, 2026: https://www.sec.gov/Archives/edgar/data/719135/000143774926031468/apyx20260929_8k.htm
- 10-K filed Mar 10, 2026: https://www.sec.gov/Archives/edgar/data/719135/000143774926007471/apyx20251231_10k.htm
- 10-Q filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/719135/000143774926026346/apyx20260630_10q.htm
- DEF 14A filed Jun 26, 2026: https://www.sec.gov/Archives/edgar/data/719135/000143774926021840/apyx20260603_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/